Whether your facility outsources or manages shortages in-house, the FDA has developed guidance to help you navigate these complex situations. From appropriate compounding of bulk substances to temporary policies for compounders not registered as outsourcing facilities, there are numerous factors to consider. Eric S. Kastango, MBA, BSPharm, FASHP and Mary Nazzal, PharmD, will walk you through the information the FDA has provided and how your facility can best support the public health effort through these difficult times.
At the conclusion of this webinar, you will be able to:
- Understand the USP 797 requirements for selection, receipt, and evaluation of all CSP components
- Discuss mitigation options and frequently asked questions on managing shortages in your sterile compounding facility
- Identify FDA and other guidance that will assist you with shortages
- Understand the USP 797 requirements for selection, receipt, and evaluation of all CSP components
- Discuss mitigation options and frequently asked questions on managing shortages in your sterile compounding facility
- Identify FDA and other guidance that will assist you with shortages
